H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Actuate Therapeutics (ACTU) to $15 from $20 and keeps a Buy rating on the shares. The firm adjusted the company’s model post the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACTU: